Cargando…
High Mutation Burden in ER-Positive/HER2-Negative/Luminal Breast Cancers
Background: Tumor mutation burden (TMB) is arising as a useful marker of checkpoint inhibitors’ effectiveness in cancer patients in general and has been proposed as predictive in breast cancers. Despite the initial success of checkpoint inhibitors in triple-negative breast cancer, ER-positive breast...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953761/ https://www.ncbi.nlm.nih.gov/pubmed/35329928 http://dx.doi.org/10.3390/jcm11061605 |